Last updated on July 2019

To Evaluate the Safety and Tolerability of Atogepant 10mg 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine


Brief description of study

To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.

Clinical Study Identifier: NCT03777059

Find a site near you

Start Over

PMG Research of Rocky Mount, LLC

Rocky Mount, NC United States
5.83miles
  Connect »